bioMérieux, French manufacturer of diagnostic solutions, has received FDA 510(k) approval for NucliSENS EasyQ MRSA, an automated molecular test for MRSA, according to a company news release.
The test detects seven MRSA types and also simultaneously detects two targets, which provides added confidence to the screening results. The EasyQ system supports batch processing of up to 46 MRSA screening tests in a compact space with a turnaround time of three hours.
Read the company news release about NucliSENS EasyQ MRSA.
Related Articles on MRSA:
Study: Hospital Employees Display Positive Perceptions Toward MRSA Screening Mandates
Study: Antibiotic Linezolid an Effective Treatment for MRSA Infection
Study: Healthcare Workers May Blame External Factors for MRSA Infections
The test detects seven MRSA types and also simultaneously detects two targets, which provides added confidence to the screening results. The EasyQ system supports batch processing of up to 46 MRSA screening tests in a compact space with a turnaround time of three hours.
Read the company news release about NucliSENS EasyQ MRSA.
Related Articles on MRSA:
Study: Hospital Employees Display Positive Perceptions Toward MRSA Screening Mandates
Study: Antibiotic Linezolid an Effective Treatment for MRSA Infection
Study: Healthcare Workers May Blame External Factors for MRSA Infections